No fads. No fearmongering. Just the stuff that works.
Retatrutide
Retatrutide's triple-hormone trial results look bigger than tirzepatide's, but they come from separate studies, not a head-to-head. And one drug is approved while the other is still investigational. Here's the honest comparison.
What the retatrutide trials reported about side effects, where the drug sits in development, and a clear warning about unregulated online versions. General info, not medical advice.
An honest look at retatrutide, Eli Lilly's investigational GIP/GLP-1/glucagon triple agonist: what trials show, its status, and sourcing risks.